Module 7 cont: NAFLD Flashcards

1
Q

What is NAFLD

A

A broad term to describe liver disease that are NOT caused by excessive alcohol consumption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is NAFLD strongly associated with

A

features of obesity, insulin resistance and T2D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

4 stages of NAFLD

A

1.Steatosis
2.Non-alcoholic steatohepatitis (NASH)
3.Cirrhosis
4. Hepatocellular carcinoma (HCC) (liver cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Reversible stages of NAFLD

A

Steatosis and NASH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Irreversible stages of NAFLD

A

Cirrhosis and HCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Symptoms of NAFLD

A

-typically asymmptomatic even in advanced stages - could be mild (fatigue)
-liver enlargement
-pain in upper right quadrant
-jaundice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Symptoms of NAFLD (cirrhosis)

A

-esophageal varices (expanded blood vessels)
-ascites
-easy bruising
-liver cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NAFLD risk factors

A

-T2D and obesity
-found in 70-80% of people who are obese or diabetic
-Age and biological sex
-more common in males, affects mainly middle aged men and elderly (post-menopausal) women
-Genetic variants
-polymorphism of PNPLA3 and TM6SF2 2 potential modifiers of progression and HFE variants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

“Two-hit hypothesis”

A

First-hit: lipid accumulation in hepatocyes
Second-hit: inflammation, oxidative stress, etc (steatosis to NASH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why does steatosis happen

A

-Imbalance in FFA levels due to an increase in hepatic FFA uptake and synthesis along w a reduction in FFA oxidation and VLDL transport

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Insulin resistance in the liver

A

-fails to supress gluconeogenesis

-continues to activate de novo lipogenesis pathway
=increase FFA and TAG accumulation in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

adipose tissue IR and FFA relationship

A

-increase in FFA (NEFA) release, increased hepatic FFA uptake
-increase TAG lipolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HSL

A

enzyme in adipose tissue that breaks down TAG into FFA
-suppressed by insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

2 major contributors to NASH development

A

-inflammation
-oxidative stress
*caused from lipotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what does dysfunctional adipose tissue release that promotes inflammation

A

proinflammatory cytokines (IL-1,IL-6.TNFa, etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fatty acids are incorporated into what

A

Saturated –> ceramides (contribute to lipotoxicity)
Mono and poly-unsaturated –> TAG (less toxic, more stable)

17
Q

High saturated fat and inflam relatioonship

A

induces inflammation and oxidative stress by activating NF-κB

18
Q

Can diet promote the “two-hits” required for NAFLD

A

-yes, diets high in sugar and saturated fats can

19
Q

what genes are potential modifiers of NAFLD

A

PNPLA3 and TM6SF2

20
Q

Where is PNPLA3 expressed and what does it do

A

-expressed in liver and adipose tissue, involved in energy mobilization and storage in lipid droplets

21
Q

PNPLA3 genotypes

A

GG, CG,CC
GG & CG - greater severity of steatosis, fibrosis and NASH

22
Q

TM6SF2 - which variant is more susceptible to NAFLD & what happens

A

E167K
Glutamate (E) replaced be lysine (K) at a.a 167

23
Q

NAFLD diagnostic challenges

A

-undiagnosed in early stages
-noninvasive diagnostic methods lack sensitivity and accuracy
-invasive method (liver biopsy) is current gold standard –> diagnose NASH and indicate severity

24
Q

3 non-invasive diagnostic NAFLD method

A
  1. ultrasound
    2.serm biomarkers
    3.proton magnetic resonance spectrometry